This bibliography references publications and case studies consistent with the indications for use of the Sonata System. For any additional information, please use the Medical/Scientific Information Request Form.
Effective November 2019
Bends R, Römer T. Hysteroskopische Resektion und Radiofrequenzablation uteriner Myome. Der Gynäkologe. 2019;52:273-279.
Bends R, Brössner A, Felberbaum R, Römer T. Myoma in statu nascendi nach transzervikaler Hochfrequenzablation eines transmuralen Leiomyoms des Uterus. Gynäkologische Endokrinologie. 2016; 14:291-294.
Bongers M, Brölmann H, Gupta J, Garza-Leal JG, Toub D. Transcervical, intrauterine ultrasound-guided radiofrequency ablation of uterine fibroids with the VizAblate® System: three- and six-month endpoint results from the FAST-EU study. Gynecol Surg. 2015; 12:61-70.
Bongers M, Quinn SD, Mueller MD et al. Evaluation of uterine patency following transcervical uterine fibroid ablation with the Sonata system (the OPEN clinical trial). Eur J Obstet Gynecol Reprod Biol. 2019;242:122-125.
Bradley LD, Pasic RP, Miller LE. Clinical Performance of Radiofrequency Ablation for Treatment of Uterine Fibroids: Systematic Review and Meta-Analysis of Prospective Studies. J Laparoendosc Adv Surg Tech. 2019; https://doi.org/10.1089/lap.2019.0550.
Brölmann H, Bongers M, Garza-Leal JG et al. The FAST-EU trial: 12-month clinical outcomes of women after intrauterine sonography-guided transcervical radiofrequency ablation of uterine fibroids. Gynecol Surg. 2016; 13:27-35.
Brooks E, Mihalov L, Delvadia D et al. The COMPARE Study: Facility Costs Associated with Hysterectomy, Myomectomy, and the Sonata Procedure for Treatment of Uterine Fibroids. Managed Care. 2019; September:40-45.
Chudnoff S, Guido R, Roy K, Levine D, Mihalov L, Garza-Leal JG. Ultrasound-Guided Transcervical Ablation of Uterine Leiomyomas. Obstet Gynecol. 2019; 133:13-22.
Garza-Leal JG, Toub D, León IH et al. Transcervical, intrauterine ultrasound-guided radiofrequency ablation of uterine fibroids with the VizAblate System: safety, tolerability, and ablation results in a closed abdomen setting. Gynecol Surg. 2011; 8:327-334.
Garza-Leal JG. Long-Term Clinical Outcomes of Transcervical Radiofrequency Ablation of Uterine Fibroids: The VITALITY Study. J Gynecol Surgery. 2019; 35:19-23.
Grube M, Neis F, Brucker SY et al. Uterine Fibroids – Current Trends and Strategies. Surg Technol Int. 2019;34:257-263.
Guido R, Stuparich M. Radiofrequency ablation: New paradigm for treatment of fibroids. Contemporary ObGyn. 2016; October:12-18.
Hudgens J, Johns DA, Lukes AS, Forstein DA, Delvadia D. 12-month outcomes of the US patient cohort in the SONATA pivotal IDE trial of transcervical ablation of uterine fibroids. Int J Womens Health. 2019; 11:387-394.
Huirne J, Brooks E. Improvement in health utility after transcervical radiofrequency ablation of uterine fibroids with the sonata system: Health utility after radiofrequency ablation. Eur J Obstet Gynecol Reprod Biol. 2018; 224:175-180.
Jones S, O’Donovan P, Toub D. Radiofrequency ablation for treatment of symptomatic uterine fibroids. Obstet Gynecol Int. 2012; 2012:194839.
Miller CE, Osman KM. Transcervical Radiofrequency Ablation of Symptomatic Uterine Fibroids: 2-Year Results. J Gynecol Surg. DOI: 10.1089/gyn.2019.0012
Taheri M, Galo L, Potts C, Sakhel K, Quinn SD. Nonresective treatments for uterine fibroids: a systematic review of uterine and fibroid volume reductions. Int J Hyperthermia. 2019;36(1):295-301.
Toub DB. A New Paradigm for Uterine Fibroid Treatment: Transcervical, Intrauterine Sonography-Guided Radiofrequency Ablation of Uterine Fibroids with the Sonata System. Curr Obstet Gynecol Rep. 2017; 6:67-73.